Monteris Medical07.21.16
Monteris Medical has appointed Martin J. Emerson as its president and CEO effective immediately.
Monteris Medical is a privately held developer of minimally invasive, MRI-guided laser ablation systems for treating brain lesions. Emerson has more than 25 years of medical device industry experience including CEO positions with both private and public companies.
“We are pleased and privileged to have an executive with Marty Emerson’s experience and track record take over the reins at Monteris Medical. He has both the leadership and market knowledge necessary to build Monteris into a world-class medical device company,” said Greg Barrett, Monteris Medical board chairman.
For the past eight years, Emerson served as president and CEO of Galil Medical, a privately held developer of cryoablation systems. During his tenure, Galil’s investment in technology and clinical research led the way to a 10-fold increase in the company’s sales within the interventional oncology market.
Galil was acquired in June 2016 by BTG plc. From 2000 to 2008, Emerson held various management positions including president and CEO with American Medical Systems (AMS), a publicly traded urology and gynecology device company with sales of more than $500 million annually. Previously, Emerson also held various domestic and international management positions with Boston Scientific Corporation and Baxter International. He currently serves on the board of directors for Vascular Solutions, Tepha Medical Devices, and Incisive Surgical.
“I would like to thank the Monteris Board of Directors for the opportunity to lead a company with such exciting technology offering minimally invasive surgical alternatives to patients with brain tumors and epilepsy. I look forward to working with the Monteris management team to meet the expectations of the company’s investors, physicians and their patients,” Emerson said.
Monteris Medical develops and markets MRI-guided laser-based systems for the ablation of brain lesions. The Monteris NeuroBlate System includes the Mini-Bolt, the only minimally invasive cranial access system that enables a robotic interface for the precise and safe delivery of laser energy. Since receiving U.S. Food and Drug Administration clearance in 2013, NeuroBlate has been used in more than 800 patient procedures across 35 installed systems in the United States and Canada.
Monteris Medical is a privately held developer of minimally invasive, MRI-guided laser ablation systems for treating brain lesions. Emerson has more than 25 years of medical device industry experience including CEO positions with both private and public companies.
“We are pleased and privileged to have an executive with Marty Emerson’s experience and track record take over the reins at Monteris Medical. He has both the leadership and market knowledge necessary to build Monteris into a world-class medical device company,” said Greg Barrett, Monteris Medical board chairman.
For the past eight years, Emerson served as president and CEO of Galil Medical, a privately held developer of cryoablation systems. During his tenure, Galil’s investment in technology and clinical research led the way to a 10-fold increase in the company’s sales within the interventional oncology market.
Galil was acquired in June 2016 by BTG plc. From 2000 to 2008, Emerson held various management positions including president and CEO with American Medical Systems (AMS), a publicly traded urology and gynecology device company with sales of more than $500 million annually. Previously, Emerson also held various domestic and international management positions with Boston Scientific Corporation and Baxter International. He currently serves on the board of directors for Vascular Solutions, Tepha Medical Devices, and Incisive Surgical.
“I would like to thank the Monteris Board of Directors for the opportunity to lead a company with such exciting technology offering minimally invasive surgical alternatives to patients with brain tumors and epilepsy. I look forward to working with the Monteris management team to meet the expectations of the company’s investors, physicians and their patients,” Emerson said.
Monteris Medical develops and markets MRI-guided laser-based systems for the ablation of brain lesions. The Monteris NeuroBlate System includes the Mini-Bolt, the only minimally invasive cranial access system that enables a robotic interface for the precise and safe delivery of laser energy. Since receiving U.S. Food and Drug Administration clearance in 2013, NeuroBlate has been used in more than 800 patient procedures across 35 installed systems in the United States and Canada.